The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT01511315
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ustekinumab — DRUG
    Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.

Study Details

This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.

Key Dates

Start date
Mar 31, 2012
Status verified
Jan 2016
Primary completion
Dec 31, 2014
Completion
Dec 31, 2014

Study Design

Enrollment
36 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ustekinumab

Primary Outcome Measure

Improvement in Quality of Life Measured by Change in Psychological General Well-Being Scale (PGWB) at Week 36 From Baseline. [ Time Frame: Baseline, 36 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Psoriasis and Skin Treatment CenterSan FranciscoCalifornia94118-

Find similar trials in San Francisco, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
UCSF Psoriasis and Skin Treatment Center· San Francisco, CA

Related Studies